Sun Pharmaceuticals Industries Ltd Analyst Rating
based on 37 analysts
75.68%
Buy
16.22%
Hold
8.11%
Sell
Based on 37 analysts offering long term price targets for Sun Pharmaceuticals Industries Ltd. An average target of ₹2043.32
Source: S&P Global Market Intelligence
Sun Pharmaceuticals Industries Ltd Share analysis
Sun Pharmaceuticals Industries Ltd price forecast by 37 analysts
Upside of12.98%
High
₹2450
Target
₹2043.32
Low
₹1600
Sun Pharmaceuticals Industries Ltd target price ₹2043.32, a slight upside of 12.98% compared to current price of ₹1800.05. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharmaceuticals Industries Ltd revenue growth forecast
Expected growth rate Q1, FY2026:20.95%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharmaceuticals Industries Ltd EPS growth forecast
EPS estimate Q1, FY2026:38.61%
Forecast
Actual
Source: S&P Global Market Intelligence
Sun Pharmaceuticals Industries Ltd Performance
Day's Low
Day's High
₹1,788.35₹1,83252 Week's Low
52 Week's High
₹1,192.35₹1,960.35
| Returns % | |
| 1 Month Return | -0.02 % |
| 3 Month Return | -0.16 % |
| 1 Year Return | + 46.9 % |
| Market Stats | |
| Previous Close | ₹1,808.55 |
| Open | ₹1,831.25 |
| Volume | 15.44L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹4,33,931.73Cr |
Sun Pharmaceuticals Industries Ltd Key Statistics
| P/E Ratio | 39.23 |
| PEG Ratio | 3.74 |
| Market Cap | ₹4,33,931.73 Cr |
| P/B Ratio | 16.41 |
| EPS | 40.21 |
| Dividend Yield | 0.83 |
| Sector | Pharmaceuticals |
| ROE | 12.05 |
Sun Pharmaceuticals Industries Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,33,931.73 Cr | 63.42% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,66,059.89 Cr | 49.69% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,13,006.93 Cr | 49.07% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹45,064.52 Cr | 6.28% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹29,327.45 Cr | -0.43% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Sun Pharmaceuticals Industries Ltd Mutual Fund Holdings
About Sun Pharmaceuticals Industries Ltd
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Share Price: ₹1800.05 per share as on 03 Dec, 2024 04:01 PM
Market Capitalisation: ₹4,33,931.73Cr as of today
Revenue: ₹13,264.22Cr as on September 2024 (Q3 24)
Net Profit: ₹3,030.67Cr as on September 2024 (Q3 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharmaceuticals Industries Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Sun Pharmaceuticals Industries Ltd
Sun Pharma Reports Strong Q2FY25 Earnings Growth - 03 Dec, 2024
Sun Pharmaceutical Industries announced a 28% year-on-year increase in consolidated net profit for Q2FY25, reaching ₹3,040.16 crore. Revenue rose nearly 10.5% to ₹13,264.22 crore, reflecting strong operational performance.Sun Pharma Stock Rises Amid Penalties Announcement - 29 Nov, 2024
Sun Pharmaceutical Industries saw a 2.94% stock increase, adding Rs 12,220 crore to its market cap. However, the Ministry of Corporate Affairs imposed penalties on directors for non-disclosure of related-party transactions.Sun Pharma Faces Penalties for Compliance Violations - 28 Nov, 2024
Sun Pharmaceutical Industries Ltd has been penalized by the Ministry of Corporate Affairs for non-disclosure and failing to obtain necessary approvals for related party transactions between 2014 and 2019. Key officials, including CMD Dilip Shanghvi, face fines totaling over Rs 45 lakh. This follows a previous SEBI investigation settled in 2021 without admission of guilt.Sun Pharma Faces Significant Customs Penalties - 26 Nov, 2024
The Office of the Commissioner of Customs has imposed a redemption fine of ₹27 lakh and a penalty of ₹1.25 crore on Sun Pharmaceutical Industries Limited for violations of the Customs Act.Sun Pharma and Alkem Respond to Drug Quality Alerts - 15 Nov, 2024
Sun Pharmaceuticals and Alkem Laboratories have clarified that they did not manufacture drugs labeled as NSQ or spurious, following a regulatory alert that could impact their reputations and finances due to misinformation.Sun Pharma's Strong Global Presence and Financial Growth - 13 Nov, 2024
Sun Pharmaceuticals, India's largest pharma company, boasts a diverse portfolio and significant US market revenue. With robust growth projections and a strong dollar benefiting exports, the company is well-positioned for continued success.Sun Pharma Faces Delays and Declining Sales - 05 Nov, 2024
Sun Pharma reported a significant decline in net sales and increased losses for September 2024. Additionally, the launch of its alopecia drug Leqselvi is delayed due to legal issues.Sun Pharma Faces Setback with Leqselvi Launch Delay - 04 Nov, 2024
Sun Pharma's planned launch of Leqselvi is delayed due to a US court injunction over patent infringement. The ruling could significantly impact projected sales and investor sentiment, leading to a 5% drop in stock price. The company plans to appeal and explore settlement options with Incyte Corporation.
Insights on Sun Pharmaceuticals Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 17.23% to 18.02% in Sep 2024 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, SUNPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 7 quarters, 1.98K Cr → 3.04K Cr (in ₹), with an average increase of 6.8% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 12.58K Cr → 13.64K Cr (in ₹), with an average increase of 4.0% per quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, SUNPHARMA stock has moved up by 24.5%
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 64.7% return, outperforming this stock by 17.8%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 9.01% to 8.89% in Sep 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 12.78% to 12.11% in Sep 2024 quarter
Sun Pharmaceuticals Industries Ltd Financials
Index Inclusions
Sun Pharmaceuticals Industries Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 18.02% | 4.60 | |
| Mutual Funds | 12.11% | ||
| Retail Investors | 8.89% | ||
| Others | 6.5% |
Sun Pharmaceuticals Industries Ltd Key Indicators
Sun Pharmaceuticals Industries Ltd Valuation
Sun Pharmaceuticals Industries Ltd in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (39.23x)
December 2, 2024
Industry (56.86x)
December 2, 2024
Highest (184.63x)
August 28, 2020
Sun Pharmaceuticals Industries Ltd Earnings and Dividends
Sun Pharmaceuticals Industries Ltd Earnings Results
Sun Pharmaceuticals Industries Ltd’s net profit jumped 27.98% since last year same period to ₹3,040.16Cr in the Q2 2024-2025. On a quarterly growth basis, Sun Pharmaceuticals Industries Ltd has generated 7.21% jump in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceuticals Industries Ltd Dividends May,2024
In the quarter ending March 2024, Sun Pharmaceuticals Industries Ltd has declared dividend of ₹5 - translating a dividend yield of 0.97%.
Read More about Dividends
Sun Pharmaceuticals Industries Ltd Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceuticals Industries Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Sun Pharmaceuticals Industries Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Sun Pharmaceuticals Industries Ltd shares.
Sun Pharmaceuticals Industries Ltd (SUNPHARMA) share price today is ₹1800.05
Sun Pharmaceuticals Industries Ltd is listed on NSE
Sun Pharmaceuticals Industries Ltd is listed on BSE
- Today’s highest price of Sun Pharmaceuticals Industries Ltd is ₹1832.
- Today’s lowest price of Sun Pharmaceuticals Industries Ltd is ₹1788.35.
PE Ratio of Sun Pharmaceuticals Industries Ltd is 39.23
PE ratio = Sun Pharmaceuticals Industries Ltd Market price per share / Sun Pharmaceuticals Industries Ltd Earnings per share
Today’s traded volume of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is 15.44L.
Today’s market capitalisation of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is ₹433931.73Cr.
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Price |
|---|---|
52 Week High | ₹1960.35 |
52 Week Low | ₹1192.35 |
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1800.05. It is down -8.18% from its 52 Week High price of ₹1960.35
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1800.05. It is up 50.97% from its 52 Week Low price of ₹1192.35
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Returns |
|---|---|
1 Day Returns | -8.5% |
1 Month Returns | -0.02% |
3 Month Returns | -0.16% |
1 Year Returns | 46.9% |